JP2023524359A5 - - Google Patents

Info

Publication number
JP2023524359A5
JP2023524359A5 JP2022554243A JP2022554243A JP2023524359A5 JP 2023524359 A5 JP2023524359 A5 JP 2023524359A5 JP 2022554243 A JP2022554243 A JP 2022554243A JP 2022554243 A JP2022554243 A JP 2022554243A JP 2023524359 A5 JP2023524359 A5 JP 2023524359A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
ctla
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022554243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524359A (ja
JP7387912B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/062695 external-priority patent/WO2021228978A1/en
Publication of JP2023524359A publication Critical patent/JP2023524359A/ja
Publication of JP2023524359A5 publication Critical patent/JP2023524359A5/ja
Priority to JP2023191381A priority Critical patent/JP2024016209A/ja
Application granted granted Critical
Publication of JP7387912B2 publication Critical patent/JP7387912B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022554243A 2020-05-12 2021-05-12 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ Active JP7387912B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023191381A JP2024016209A (ja) 2020-05-12 2023-11-09 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023554P 2020-05-12 2020-05-12
US63/023,554 2020-05-12
PCT/EP2021/062695 WO2021228978A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191381A Division JP2024016209A (ja) 2020-05-12 2023-11-09 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ

Publications (3)

Publication Number Publication Date
JP2023524359A JP2023524359A (ja) 2023-06-12
JP2023524359A5 true JP2023524359A5 (cg-RX-API-DMAC7.html) 2023-06-26
JP7387912B2 JP7387912B2 (ja) 2023-11-28

Family

ID=75977756

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554243A Active JP7387912B2 (ja) 2020-05-12 2021-05-12 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ
JP2023191381A Pending JP2024016209A (ja) 2020-05-12 2023-11-09 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023191381A Pending JP2024016209A (ja) 2020-05-12 2023-11-09 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ

Country Status (12)

Country Link
US (3) US20210355224A1 (cg-RX-API-DMAC7.html)
EP (1) EP4021940A1 (cg-RX-API-DMAC7.html)
JP (2) JP7387912B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230009354A (cg-RX-API-DMAC7.html)
CN (1) CN114729054A (cg-RX-API-DMAC7.html)
AU (3) AU2021269832B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022021893A2 (cg-RX-API-DMAC7.html)
CA (2) CA3158607A1 (cg-RX-API-DMAC7.html)
IL (3) IL328607A (cg-RX-API-DMAC7.html)
MX (1) MX2022006728A (cg-RX-API-DMAC7.html)
TW (2) TWI870592B (cg-RX-API-DMAC7.html)
WO (1) WO2021228978A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260077026A1 (en) * 2022-09-07 2026-03-19 The University Of Chicago Methods for treating cancer with hyperactive adar enzymes
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트
TW202617179A (zh) * 2024-06-13 2026-05-01 大陸商江蘇恆瑞醫藥股份有限公司 抗pd-l1抗體和抗ctla-4抗體聯合治療腫瘤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087339A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
JP2006512102A (ja) 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180079814A1 (en) * 2015-04-01 2018-03-22 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
JP7085709B2 (ja) * 2016-06-20 2022-06-17 エフ-スター セラピューティクス リミテッド Pd-l1及びlag-3に結合する結合分子
JP2019537619A (ja) * 2016-09-27 2019-12-26 オンコロジー、インコーポレイテッド β2−糖タンパク質1のレベルに基づいて、バビツキシマブで癌を治療するための方法、およびそのためのアッセイ
KR20200020662A (ko) * 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
AU2018273988C1 (en) * 2017-05-26 2025-11-13 Bruin Biosciences, Inc. Chemoembolization agents
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US20210260051A1 (en) * 2018-06-14 2021-08-26 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
CA3102334A1 (en) * 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Similar Documents

Publication Publication Date Title
JP2024016209A5 (cg-RX-API-DMAC7.html)
JP2023507190A5 (cg-RX-API-DMAC7.html)
JP2021514969A5 (cg-RX-API-DMAC7.html)
JP2014533279A5 (cg-RX-API-DMAC7.html)
JP2013533858A5 (cg-RX-API-DMAC7.html)
JP2007515469A5 (cg-RX-API-DMAC7.html)
JP2017501167A5 (cg-RX-API-DMAC7.html)
JP2021510697A5 (cg-RX-API-DMAC7.html)
JP2012509889A5 (cg-RX-API-DMAC7.html)
JP2021513536A5 (cg-RX-API-DMAC7.html)
RU2018146812A (ru) Фармацевтические комбинации
JP2018522028A5 (cg-RX-API-DMAC7.html)
JP2010515774A5 (cg-RX-API-DMAC7.html)
JP2017537927A5 (cg-RX-API-DMAC7.html)
JP2022518232A5 (cg-RX-API-DMAC7.html)
JP2021528438A5 (cg-RX-API-DMAC7.html)
JP2021509395A5 (cg-RX-API-DMAC7.html)
JP2024533067A5 (cg-RX-API-DMAC7.html)
JP2023510199A5 (cg-RX-API-DMAC7.html)
JP2023545084A5 (cg-RX-API-DMAC7.html)
JP2023102786A5 (cg-RX-API-DMAC7.html)
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
CN113599527B (zh) Apoe抑制剂与pd-1单抗联用在制备治疗消化道肿瘤的药物中的应用
JP2023531200A5 (cg-RX-API-DMAC7.html)
JP2019534251A5 (cg-RX-API-DMAC7.html)